Clinical trials: Transplants
End-Stage Renal Disease, Hepatitis C
Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time.
- Trial name
- EXPANDER-1 (NCT02781649)
- Testing
- Zepatier, Ribavirin, Sofosbuvir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Cytomegalovirus (CMV)
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after…
- Trial name
- NCT02927067
- Testing
- Maribavir, Valganciclovir
- Where
- 129 sites in United States, Australia and 21 more
- Volunteers
- 553 people
- Sponsor
- Shire
Squamous Cell Carcinoma
Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
Using focus group and cognitive interviews with organ transplant recipients, the investigators developed interactive workbooks: a) prevention by sun protection b) early detection by skin self-examination (SSE).
- Trial name
- SCCs in OTRs (NCT01127737)
- Testing
- Educational Intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Northwestern University
Cytomegalovirus Disease
Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
The purpose of the study is to assess the incidence and severity of late Cytomegalovirus (CMV) disease, defined as CMV syndrome or tissue invasive disease occurring between 100 and 200 days and after 200 days post-transplant in…
- Trial name
- NCT01509404
- Testing
- Valganciclovir, CMV hyperimmune globulin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina
Liver Transplantation
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
The purpose of this trial was to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.
- Trial name
- NCT01888432
- Testing
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Where
- 42 sites in United States, Canada and 11 more
- Volunteers
- 285 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation, Graft Rejection
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.
- Trial name
- NCT00251004
- Testing
- Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA)
- Where
- United States
- Volunteers
- 833 people
- Sponsor
- Novartis
Prophylaxis Of Invasive Fungal Infections
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
- Trial name
- VOSIFI (NCT00143312)
- Testing
- voriconazole
- Where
- 17 sites in Belgium, France and 6 more
- Volunteers
- 45 people
- Sponsor
- Pfizer
Transplants and Implants
Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant
The purpose of the study was to determine if rapid discontinuation of corticosteroids (also known as prednisone withdrawal) and maintenance immunosuppression with Prograf (tacrolimus) and CellCept (mycophenolate mofetil) while…
- Trial name
- NCT00596947
- Testing
- prednisone, rabbit antithymocyte globulin, Tacrolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Pennsylvania
Clostridium Difficile Infection Recurrence
Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients
The objective is to examine the effect of Fecal Microbiota Transplantation (FMT) compared with vancomycin for cure of recurrent C.
- Trial name
- NCT03617445
- Testing
- FMT oral capsule, Oral Vancomycin
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Immunosuppression, Kidney Transplantation
The Differential Effects of 3 Different Immunosuppressive
The study is a laboratory investigation comparing the regulatory effects of different immunosuppressive therapies in an in vitro human MLR assay of selecting specific immunosuppressive therapy to promote a regulatory profile and…
- Trial name
- NCT00729248
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Hepatitis C, Kidney Transplant; Complications
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
- Conditions
- Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
- Trial name
- NCT04508907
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mayo Clinic
Organ Transplant
DCD IIT: Evaluating the Safety of Utilizing Donor Hearts From Donation After Circulatory Death (DCD) Donors
The purpose the research is to evaluate whether patients who receive a Donation after Circulatory Death (DCD) heart for cardiac transplantation using either normothermic regional perfusion (NRP) or direct procurement and…
- Trial name
- NCT05462041
- Testing
- DBD Donor Heart Transplantation, DCD Donor Heart Transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cedars-Sinai Medical Center
Refractory Multiple Myeloma, Stage II Multiple Myeloma
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
RATIONALE: Giving chemotherapy drugs, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00217438
- Testing
- melphalan, amifostine trihydrate, peripheral blood stem cell transplantation
- Where
- 4 sites in United States
- Volunteers
- 130 people
- Sponsor
- Fred Hutchinson Cancer Center
Immunosuppression in Solid Organ Transplant
Belatacept in Liver Transplant Recipients
The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant
- Trial name
- NCT00555321
- Testing
- Tacrolimus, Basiliximab, Belatacept More Intensive (MI)
- Where
- 42 sites in United States, Argentina and 7 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Cemiplimab in AlloSCT/SOT Recipients With CSCC
In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney…
- Trial name
- CONTRAC (NCT04339062)
- Testing
- Cemiplimab, Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Cytomegalovirus (CMV)
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
The main aim of the study is to check if maribavir can treat Japanese people with Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting…
- Trial name
- NCT05137717
- Testing
- Maribavir
- Where
- 20 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Takeda
Pancreas Transplantation, Kidney Transplantation
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants
Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients.
- Trial name
- NCT00267150
- Testing
- Enteric-coated mycophenolate sodium (EC-MPS)
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Antifungal Prophylaxis of Invasive Fungal Infections
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Study is to compare antifungal prophylaxis of Voriconazole and Itraconazole in subjects who have had a Stem Cell Transplant. The success of the end point will be measured using evidence of Infection, drug compliance and survival.
- Trial name
- IMPROVIT (NCT00289991)
- Testing
- Itraconazole, Vfend - voriconazole
- Where
- 49 sites in Canada, Czechia and 10 more
- Volunteers
- 489 people
- Sponsor
- Pfizer
Lymphoproliferative Disorder
Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD
RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients who are being…
- Trial name
- NCT00278200
- Testing
- Inactivated EBV-infected vaccine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hiv
HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
The primary objective of this study is to determine if an HIV-infected deceased kidney donor (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications.
- Trial name
- NCT03500315
- Testing
- HIV D+/R+
- Where
- 29 sites in United States
- Volunteers
- 207 people
- Sponsor
- Johns Hopkins University